Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.64 |
| ▸ | PI4KA | P42356 | 10/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28413958 | 0.98 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28410735 | 0.96 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29242837 | 0.84 | YTHDC1 (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL120720 | 0.84 | ADORA2A (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28560268 | 0.83 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3506547 | 0.82 | ADORA2A (0.46) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10460432 | 0.82 | ADORA2A (0.46) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL667204 | 0.80 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1065184 | 0.79 | ADORA2A (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1831279 | 0.79 | XDH (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109390037-A | The full site recognition methods of mature miRNA based on SVM-AdaBoost | 齐齐哈尔大学 | 2019-02-26 | — | — | CN | claimed |
| US-20100311175-A1 | MASS TAGS FOR QUANTITATIVE ANALYSES | Life Technologies Corporation (US) | 2010-12-09 | — | — | US | claimed |
| US-20080196121-A1 | Commercially viable process for in vitro mass culture of jatropha curcas | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2008-08-14 | — | — | US | claimed |
| EP-1817956-A2 | Commercially viable process for in-vitro mass culture of jatropha curcas | Reliance Life Sciences Pvt., Ltd. (IN) | 2007-08-15 | — | — | EP | claimed |
| CN-115340478-A | Schiff base ligand and preparation method and application of polynuclear rare earth complex thereof | 温州医科大学 | 2022-11-15 | — | — | CN | disclosed |
| CN-115266662-A | Hyperspectral sequencing method and system and gene sequencer | 深圳赛陆医疗科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114438180-A | Single nucleotide mutation detection method based on photoacoustic quantitative detection equipment | 中南大学 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021076887-A1 | CAL-T CONSTRUCTS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| CN-109390037-A | The full site recognition methods of mature miRNA based on SVM-AdaBoost | 齐齐哈尔大学 | 2019-02-26 | — | — | CN | disclosed |
| CN-104771601-B | A kind of combination agent for improving blood viscosity and hematoblastic aggregation | 张坤镛 | 2018-06-19 | — | — | CN | disclosed |
| CN-107208029-A | Lactic acid bacteria of ability and application thereof is absorbed with purine | 株式会社明治 | 2017-09-26 | — | — | CN | disclosed |
| WO-1999009044-A1 | RIBONUCLEOSIDE-DERIVATIVE AND METHOD FOR PREPARING THE SAME | PITSCH STEFAN (CH) | 1999-02-25 | — | — | WO | disclosed |
| US-5817812-A | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | KURARAY CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0775705-A2 | Cyclopentenecarboxamide derivative, method for preparing the same and bicycloamide derivative used therein | KURARAY CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
| US-5217858-A | Radiation sensitive silver halide emulsion containing at least fifty mole percent silver chloride grains which have crystal face stabilizer adsorbed onto the faces thereof | EASTMAN KODAK COMPANY (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0394346-A4 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | US HEALTH (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0394346-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1990-10-31 | — | — | EP | disclosed |
| WO-1989006235-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-07-13 | — | — | WO | disclosed |
| US-4639531-A | HETEROCYCLIC AMIDINE CATALYST | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311175-A1 | MASS TAGS FOR QUANTITATIVE ANALYSES | SRMS, PTMS, TMT1A | ADORA2A 4342/4885ADORA1 4573/4885PI4KA 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.